These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

639 related items for PubMed ID: 8996185

  • 1. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [Abstract] [Full Text] [Related]

  • 2. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [Abstract] [Full Text] [Related]

  • 3. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality.
    Möller HJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1101-11. PubMed ID: 14642970
    [Abstract] [Full Text] [Related]

  • 4. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
    Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, Costentin J, Schoenfelder A, Garrido F, Mann A.
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
    [Abstract] [Full Text] [Related]

  • 5. Amisulpride: from animal pharmacology to therapeutic action.
    Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H.
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S29-36. PubMed ID: 9218165
    [Abstract] [Full Text] [Related]

  • 6. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW.
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
    [Abstract] [Full Text] [Related]

  • 7. Is amisulpride an 'atypical' atypical antipsychotic agent?
    Lecrubier Y.
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
    [Abstract] [Full Text] [Related]

  • 8. Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons.
    Di Giovanni G, Di Mascio M, Di Matteo V, Esposito E.
    J Pharmacol Exp Ther; 1998 Oct; 287(1):51-7. PubMed ID: 9765321
    [Abstract] [Full Text] [Related]

  • 9. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL.
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [Abstract] [Full Text] [Related]

  • 10. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ, Svenningsson P, Ashby CR, Hill M, Egeland M, Dekeyne A, Brocco M, Di Cara B, Lejeune F, Thomasson N, Munoz C, Mocaër E, Crossman A, Cistarelli L, Girardon S, Iob L, Veiga S, Gobert A.
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [Abstract] [Full Text] [Related]

  • 11. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS.
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [Abstract] [Full Text] [Related]

  • 12. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.
    Kiss B, Laszlovszky I, Horváth A, Némethy Z, Schmidt E, Bugovics G, Fazekas K, Gyertyán I, Agai-Csongor E, Domány G, Szombathelyi Z.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):515-28. PubMed ID: 18551280
    [Abstract] [Full Text] [Related]

  • 13. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol.
    de Bartolomeis A, Marmo F, Buonaguro EF, Rossi R, Tomasetti C, Iasevoli F.
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1516-29. PubMed ID: 23357084
    [Abstract] [Full Text] [Related]

  • 14. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
    Audinot V, Newman-Tancredi A, Gobert A, Rivet JM, Brocco M, Lejeune F, Gluck L, Desposte I, Bervoets K, Dekeyne A, Millan MJ.
    J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
    [Abstract] [Full Text] [Related]

  • 15. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
    Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newman-Tancredi A, Dacquet C, Bervoets K, Girardon S.
    J Pharmacol Exp Ther; 1995 Nov; 275(2):885-98. PubMed ID: 7473180
    [Abstract] [Full Text] [Related]

  • 16. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat.
    Cudennec A, Fage D, Bénavidès J, Scatton B.
    Brain Res; 1997 Sep 12; 768(1-2):257-65. PubMed ID: 9369323
    [Abstract] [Full Text] [Related]

  • 17. From pharmacological profiles to clinical outcomes.
    Kerwin R.
    Int Clin Psychopharmacol; 2000 Dec 12; 15 Suppl 4():S1-4. PubMed ID: 11252517
    [Abstract] [Full Text] [Related]

  • 18. Expression and pharmacological characterization of the human D3 dopamine receptor.
    Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G.
    J Pharmacol Exp Ther; 1994 Jan 12; 268(1):417-26. PubMed ID: 8301582
    [Abstract] [Full Text] [Related]

  • 19. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G.
    J Pharmacol Exp Ther; 1998 Sep 12; 286(3):1341-55. PubMed ID: 9732398
    [Abstract] [Full Text] [Related]

  • 20. Dopamine receptor regulation of Ca2+ levels in individual isolated nerve terminals from rat striatum: comparison of presynaptic D1-like and D2-like receptors.
    Wu J, Dougherty JJ, Nichols RA.
    J Neurochem; 2006 Jul 12; 98(2):481-94. PubMed ID: 16805841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.